Design of new inhibitors of HIV-1 aspartic protease

被引：15

作者：

Miertus, S ^{[1
]}

Furlan, M ^{[1
]}

Tossi, A ^{[1
]}

Romeo, D ^{[1
]}

机构：

[1] UNIV TRIESTE,DEPT BIOCHEM BIOPHYS & MACROMOLEC CHEM,I-34127 TRIESTE,ITALY

来源：

CHEMICAL PHYSICS | 1996年 / 204卷 / 2-3期

关键词：

D O I：

10.1016/0301-0104(95)00363-0

中图分类号：

O64 [物理化学（理论化学）、化学物理学];

学科分类号：

070304 ; 081704 ;

摘要：

We present an approach for designing new inhibitors (I) of HIV-1 aspartic protease (PR) based on calculation of relative binding energies, taking into account contributions from all species involved in the complexation equilibrium (I + PR double left right arrow I:PR), as well as their solvation. This allows a rational design of new structures with predicted enhanced inhibitory potency. We have also analysed the role in binding affinity of the central non-scissile bond (X1-X2) as well as of flanking aminoacid residues Pn of inhibitor structures (P3-P2-P1-X1'-X2'-P2'-P3').

引用

页码：173 / 180

页数：8

共 22 条

[1] INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS-1 PROTEASE BY A C2-SYMMETRICAL PHOSPHINATE - SYNTHESIS AND CRYSTALLOGRAPHIC ANALYSIS
ABDELMEGUID, SS
ZHAO, BG
MURTHY, KHM
WINBORNE, E
CHOI, JK
DESJARLAIS, RL
MINNICH, MD
CULP, JS
DEBOUCK, C
TOMASZEK, TA
MEEK, TD
DREYER, GB
[J]. BIOCHEMISTRY, 1993, 32 (31) : 7972 - 7980
[2] STRUCTURE-BASED DRUG DESIGN
COLMAN, PM
[J]. CURRENT OPINION IN STRUCTURAL BIOLOGY, 1994, 4 (06) : 868 - 874
[3] STRUCTURE AND ENERGETICS OF LIGAND-BINDING TO PROTEINS - ESCHERICHIA-COLI DIHYDROFOLATE REDUCTASE TRIMETHOPRIM, A DRUG-RECEPTOR SYSTEM
DAUBEROSGUTHORPE, P
ROBERTS, VA
OSGUTHORPE, DJ
WOLFF, J
GENEST, M
HAGLER, AT
[J]. PROTEINS-STRUCTURE FUNCTION AND GENETICS, 1988, 4 (01): : 31 - 47
[4] HIV PROTEASE LIGAND COMPLEXES
FITZGERALD, PMD
[J]. CURRENT OPINION IN STRUCTURAL BIOLOGY, 1993, 3 (06) : 868 - 874
[5] EXTENDING CRYSTALLOGRAPHIC INFORMATION WITH SEMIEMPIRICAL QUANTUM-MECHANICS AND MOLECULAR MECHANICS - A CASE OF ASPARTIC PROTEINASES
GOLDBLUM, A
RAYAN, A
FLIESS, A
GLICK, M
[J]. JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 1993, 33 (02): : 270 - 274
[6] A-PRIORI PREDICTION OF ACTIVITY FOR HIV-1 PROTEASE INHIBITORS EMPLOYING ENERGY MINIMIZATION IN THE ACTIVE-SITE
HOLLOWAY, MK
WAI, JM
HALGREN, TA
FITZGERALD, PMD
VACCA, JP
DORSEY, BD
LEVIN, RB
THOMPSON, WJ
CHEN, LJ
DESOLMS, SJ
GAFFIN, N
GHOSH, AK
GIULIANI, EA
GRAHAM, SL
GUARE, JP
HUNGATE, RW
LYLE, TA
SANDERS, WM
TUCKER, TJ
WIGGINS, M
WISCOUNT, CM
WOLTERSDORF, OW
YOUNG, SD
DARKE, PL
ZUGAY, JA
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (02) : 305 - 317
[7] HUMAN IMMUNODEFICIENCY VIRUS-1 PROTEASE .2. USE OF PH RATE STUDIES AND SOLVENT KINETIC ISOTOPE EFFECTS TO ELUCIDATE DETAILS OF CHEMICAL MECHANISM
HYLAND, LJ
TOMASZEK, TA
MEEK, TD
[J]. BIOCHEMISTRY, 1991, 30 (34) : 8454 - 8463
[8] STRUCTURE AT 2.5-A RESOLUTION OF CHEMICALLY SYNTHESIZED HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROTEASE COMPLEXED WITH A HYDROXYETHYLENE-BASED INHIBITOR
JASKOLSKI, M
TOMASSELLI, AG
SAWYER, TK
STAPLES, DG
HEINRIKSON, RL
SCHNEIDER, J
KENT, SBH
WLODAWER, A
[J]. BIOCHEMISTRY, 1991, 30 (06) : 1600 - 1609
[9] STRUCTURE-BASED MOLECULAR DESIGN
KUNTZ, ID
MENG, EC
SHOICHET, BK
[J]. ACCOUNTS OF CHEMICAL RESEARCH, 1994, 27 (05) : 117 - 123
[10] LOFTUS R, 1995, GMHC NEWS EXP AIDS T, V9, P1

← 1 2 3 →